ALTUVIIIO [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] is a sterile, non-pyrogenic, white to off-white lyophilized powder for reconstitution for intravenous injection. …

Once-weekly ALTUVIIIO is a first-in-class, high-sustained Factor VIII replacement therapy that provides normal to near-normal levels (>40%) for most of the week in adults. 1* Learn more …

ALTUVIIIO is a first-in-class Factor VIII replacement therapy that keeps Factor VIII levels above 40% (near-normal to normal range) for most of the week in adults and for ~3 days in kids–with …

Feb 23, 2021 · ALTUVIIIO is indicated for routine prophylaxis and on-demand treatment to control bleeding episodes, as well as perioperative management (surgery) for adults and children with …

ALTUVIIIO [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] is a recombi- nant DNA-derived, Factor VIII concentrate indicated for use in adults and children with …

May 10, 2024 · ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl] is a first-in-class high-sustained factor VIII therapy that is designed to extend protection …

Find out more about the adult and adolescent trial with the ALTUVIIIO safety profile. ALTUVIIIO has efficacy data in the prophylaxis, on-demand, and perioperative settings for children.

For adults and children with Hemophilia A (congenital Factor VIII deficiency) for: (1) Routine prophylaxis to reduce the frequency of bleeding episodes; (2) On-demand treatment and …

Other. ALTUVIIIO® [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl]

ALTUVIIIO® [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] is a von Willebrand Factor (VWF) independent recombinant DNA-derived, Factor VIII concentrate …